Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Net Income (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed Net Income for 8 consecutive years, with -$59.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income fell 16.16% year-over-year to -$59.1 million, compared with a TTM value of -$71.0 million through Sep 2025, up 58.28%, and an annual FY2024 reading of $10.6 million, up 105.75% over the prior year.
  • Net Income was -$59.1 million for Q3 2025 at Bicycle Therapeutics, up from -$79.0 million in the prior quarter.
  • Across five years, Net Income topped out at $127.8 million in Q4 2024 and bottomed at -$79.0 million in Q2 2025.
  • Average Net Income over 5 years is -$29.1 million, with a median of -$30.0 million recorded in 2022.
  • The sharpest move saw Net Income soared 341.79% in 2024, then plummeted 128.72% in 2025.
  • Year by year, Net Income stood at -$19.1 million in 2021, then crashed by 57.19% to -$30.0 million in 2022, then crashed by 76.23% to -$52.9 million in 2023, then soared by 341.79% to $127.8 million in 2024, then plummeted by 146.21% to -$59.1 million in 2025.
  • Business Quant data shows Net Income for BCYC at -$59.1 million in Q3 2025, -$79.0 million in Q2 2025, and -$60.8 million in Q1 2025.